Rats subject to extracorporeal membrane oxygenation have improved cardiac function following anticoagulation and reversal with factor IXa aptamer-antidote oligonucleotide pair Article Swipe
Shahid M. Nimjee
,
Fellery de Lange
,
George A. Pitoc
,
Bruce A. Sullenger
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1097/cp9.0000000000000122
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1097/cp9.0000000000000122
Background and purpose: Unfractionated heparin (UFH) is the most commonly utilized rapid-onset anticoagulant, valued for its potency and reversibility with protamine. However, UFH and protamine are associated with significant side effects, including increased morbidity and mortality, and concerns about sustainability due to the environmental impact of large-scale pig farming for heparin production. This study evaluates an alternative anticoagulant strategy using a factor IXa (FIXa) aptamer paired with a matched oligonucleotide antidote, comparing its efficacy and safety to heparin-protamine in a rat extracorporeal membrane oxygenation (ECMO) model. Methods: Twenty-four Sprague-Dawley rats were randomized into two groups: one receiving heparin (600 IU/kg) and protamine (1 mg/100 IU heparin), and the other receiving a cholesterol-modified FIXa aptamer (10 mg/kg) and its antidote (50 mg/kg). Coagulation parameters, platelet counts, inflammatory markers, cardiac function, and histopathology were assessed during and after 60 minutes of ECMO. Results: The FIXa aptamer effectively maintained circuit patency without clot formation, comparable to heparin. The antidote rapidly reversed the aptamer’s anticoagulant activity, similar to protamine’s reversal of heparin. Notably, the aptamer-antidote group demonstrated superior outcomes, including improved mean arterial pressure (58 ± 6 mmHg vs. 54 ± 3 mmHg at 30 minutes; 59 ± 8 mmHg vs. 51 ± 5 mmHg at 3 hours post-ECMO) and cardiac function (shortening fraction: 60 ± 16% vs. 42 ± 8%; P = 0.01). Additionally, the aptamer group exhibited better platelet preservation (platelet count decrease: −288,000 ± 121,000/μL vs. −404,000 ± 89,000/μL; P = 0.03). Inflammatory profiles were similar between groups, except for a transient increase in interleukins 10 (IL-10) in the aptamer group. Histopathological analysis revealed no significant differences in myocardial lesions. Conclusions: The antidote-controlled anti-FIXa aptamer represents an alternative anticoagulant strategy that may prove useful for managing patients with a history of heparin-induced thrombocytopenia (HIT) and myocardial dysfunction associated with protamine administration.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1097/cp9.0000000000000122
- OA Status
- diamond
- Cited By
- 1
- References
- 48
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4411582169
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4411582169Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1097/cp9.0000000000000122Digital Object Identifier
- Title
-
Rats subject to extracorporeal membrane oxygenation have improved cardiac function following anticoagulation and reversal with factor IXa aptamer-antidote oligonucleotide pairWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-04-01Full publication date if available
- Authors
-
Shahid M. Nimjee, Fellery de Lange, George A. Pitoc, Bruce A. SullengerList of authors in order
- Landing page
-
https://doi.org/10.1097/cp9.0000000000000122Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
diamondOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1097/cp9.0000000000000122Direct OA link when available
- Concepts
-
Antidote, Protamine, Heparin, Extracorporeal membrane oxygenation, Medicine, Pharmacology, Anticoagulant, Anesthesia, Internal medicine, ToxicityTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
1Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 1Per-year citation counts (last 5 years)
- References (count)
-
48Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4411582169 |
|---|---|
| doi | https://doi.org/10.1097/cp9.0000000000000122 |
| ids.doi | https://doi.org/10.1097/cp9.0000000000000122 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40599554 |
| ids.openalex | https://openalex.org/W4411582169 |
| fwci | 6.62138127 |
| type | article |
| title | Rats subject to extracorporeal membrane oxygenation have improved cardiac function following anticoagulation and reversal with factor IXa aptamer-antidote oligonucleotide pair |
| biblio.issue | 2 |
| biblio.volume | 10 |
| biblio.last_page | 98 |
| biblio.first_page | 87 |
| topics[0].id | https://openalex.org/T12352 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9987999796867371 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2746 |
| topics[0].subfield.display_name | Surgery |
| topics[0].display_name | Heparin-Induced Thrombocytopenia and Thrombosis |
| topics[1].id | https://openalex.org/T10881 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9979000091552734 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2720 |
| topics[1].subfield.display_name | Hematology |
| topics[1].display_name | Blood Coagulation and Thrombosis Mechanisms |
| topics[2].id | https://openalex.org/T11353 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.9977999925613403 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1311 |
| topics[2].subfield.display_name | Genetics |
| topics[2].display_name | Venomous Animal Envenomation and Studies |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2779365888 |
| concepts[0].level | 3 |
| concepts[0].score | 0.8848164081573486 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q194168 |
| concepts[0].display_name | Antidote |
| concepts[1].id | https://openalex.org/C2780835560 |
| concepts[1].level | 3 |
| concepts[1].score | 0.7625466585159302 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q5449573 |
| concepts[1].display_name | Protamine |
| concepts[2].id | https://openalex.org/C2777557582 |
| concepts[2].level | 2 |
| concepts[2].score | 0.7396007776260376 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q190016 |
| concepts[2].display_name | Heparin |
| concepts[3].id | https://openalex.org/C2776858399 |
| concepts[3].level | 2 |
| concepts[3].score | 0.6607100367546082 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q1385195 |
| concepts[3].display_name | Extracorporeal membrane oxygenation |
| concepts[4].id | https://openalex.org/C71924100 |
| concepts[4].level | 0 |
| concepts[4].score | 0.602939784526825 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[4].display_name | Medicine |
| concepts[5].id | https://openalex.org/C98274493 |
| concepts[5].level | 1 |
| concepts[5].score | 0.5175558924674988 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[5].display_name | Pharmacology |
| concepts[6].id | https://openalex.org/C2778205648 |
| concepts[6].level | 2 |
| concepts[6].score | 0.4789626896381378 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q215118 |
| concepts[6].display_name | Anticoagulant |
| concepts[7].id | https://openalex.org/C42219234 |
| concepts[7].level | 1 |
| concepts[7].score | 0.4700689911842346 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q131130 |
| concepts[7].display_name | Anesthesia |
| concepts[8].id | https://openalex.org/C126322002 |
| concepts[8].level | 1 |
| concepts[8].score | 0.28127312660217285 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[8].display_name | Internal medicine |
| concepts[9].id | https://openalex.org/C29730261 |
| concepts[9].level | 2 |
| concepts[9].score | 0.11957323551177979 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q274160 |
| concepts[9].display_name | Toxicity |
| keywords[0].id | https://openalex.org/keywords/antidote |
| keywords[0].score | 0.8848164081573486 |
| keywords[0].display_name | Antidote |
| keywords[1].id | https://openalex.org/keywords/protamine |
| keywords[1].score | 0.7625466585159302 |
| keywords[1].display_name | Protamine |
| keywords[2].id | https://openalex.org/keywords/heparin |
| keywords[2].score | 0.7396007776260376 |
| keywords[2].display_name | Heparin |
| keywords[3].id | https://openalex.org/keywords/extracorporeal-membrane-oxygenation |
| keywords[3].score | 0.6607100367546082 |
| keywords[3].display_name | Extracorporeal membrane oxygenation |
| keywords[4].id | https://openalex.org/keywords/medicine |
| keywords[4].score | 0.602939784526825 |
| keywords[4].display_name | Medicine |
| keywords[5].id | https://openalex.org/keywords/pharmacology |
| keywords[5].score | 0.5175558924674988 |
| keywords[5].display_name | Pharmacology |
| keywords[6].id | https://openalex.org/keywords/anticoagulant |
| keywords[6].score | 0.4789626896381378 |
| keywords[6].display_name | Anticoagulant |
| keywords[7].id | https://openalex.org/keywords/anesthesia |
| keywords[7].score | 0.4700689911842346 |
| keywords[7].display_name | Anesthesia |
| keywords[8].id | https://openalex.org/keywords/internal-medicine |
| keywords[8].score | 0.28127312660217285 |
| keywords[8].display_name | Internal medicine |
| keywords[9].id | https://openalex.org/keywords/toxicity |
| keywords[9].score | 0.11957323551177979 |
| keywords[9].display_name | Toxicity |
| language | en |
| locations[0].id | doi:10.1097/cp9.0000000000000122 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4210203274 |
| locations[0].source.issn | 2470-7511, 2470-752X |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2470-7511 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Cardiology Plus |
| locations[0].source.host_organization | https://openalex.org/P4310315671 |
| locations[0].source.host_organization_name | Lippincott Williams & Wilkins |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310315671 |
| locations[0].license | cc-by-nc-nd |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc-nd |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Cardiology Plus |
| locations[0].landing_page_url | https://doi.org/10.1097/cp9.0000000000000122 |
| locations[1].id | pmid:40599554 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Cardiology plus |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40599554 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:12208382 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Cardiol Plus |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/12208382 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5016424099 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-0317-8731 |
| authorships[0].author.display_name | Shahid M. Nimjee |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I2802841970, https://openalex.org/I52357470 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Neurosurgery, The Ohio State University Medical Center, Columbus, Ohio 43210, USA. |
| authorships[0].institutions[0].id | https://openalex.org/I52357470 |
| authorships[0].institutions[0].ror | https://ror.org/00rs6vg23 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I52357470 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | The Ohio State University |
| authorships[0].institutions[1].id | https://openalex.org/I2802841970 |
| authorships[0].institutions[1].ror | https://ror.org/00c01js51 |
| authorships[0].institutions[1].type | healthcare |
| authorships[0].institutions[1].lineage | https://openalex.org/I2802841970 |
| authorships[0].institutions[1].country_code | US |
| authorships[0].institutions[1].display_name | The Ohio State University Wexner Medical Center |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Shahid M. Nimjee |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Neurosurgery, The Ohio State University Medical Center, Columbus, Ohio 43210, USA. |
| authorships[1].author.id | https://openalex.org/A5103538486 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Fellery de Lange |
| authorships[1].countries | NL |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I2802652803 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Intensive Care, Medical Center Leeuwarden, Leeuwarden 8901 BR, The Netherlands. |
| authorships[1].institutions[0].id | https://openalex.org/I2802652803 |
| authorships[1].institutions[0].ror | https://ror.org/0283nw634 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I2802652803 |
| authorships[1].institutions[0].country_code | NL |
| authorships[1].institutions[0].display_name | Medisch Centrum Leeuwarden |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Fellery de Lange |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Intensive Care, Medical Center Leeuwarden, Leeuwarden 8901 BR, The Netherlands. |
| authorships[2].author.id | https://openalex.org/A5003733132 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | George A. Pitoc |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210126298, https://openalex.org/I4210153043 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA. |
| authorships[2].institutions[0].id | https://openalex.org/I4210126298 |
| authorships[2].institutions[0].ror | https://ror.org/03njmea73 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210126298, https://openalex.org/I4210144876 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Duke Medical Center |
| authorships[2].institutions[1].id | https://openalex.org/I4210153043 |
| authorships[2].institutions[1].ror | https://ror.org/04bct7p84 |
| authorships[2].institutions[1].type | healthcare |
| authorships[2].institutions[1].lineage | https://openalex.org/I4210126298, https://openalex.org/I4210144876, https://openalex.org/I4210144876, https://openalex.org/I4210153043 |
| authorships[2].institutions[1].country_code | US |
| authorships[2].institutions[1].display_name | Duke University Hospital |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | George A. Pitoc |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA. |
| authorships[3].author.id | https://openalex.org/A5040370918 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-5113-5541 |
| authorships[3].author.display_name | Bruce A. Sullenger |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210126298, https://openalex.org/I4210153043 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA. |
| authorships[3].institutions[0].id | https://openalex.org/I4210126298 |
| authorships[3].institutions[0].ror | https://ror.org/03njmea73 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210126298, https://openalex.org/I4210144876 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Duke Medical Center |
| authorships[3].institutions[1].id | https://openalex.org/I4210153043 |
| authorships[3].institutions[1].ror | https://ror.org/04bct7p84 |
| authorships[3].institutions[1].type | healthcare |
| authorships[3].institutions[1].lineage | https://openalex.org/I4210126298, https://openalex.org/I4210144876, https://openalex.org/I4210144876, https://openalex.org/I4210153043 |
| authorships[3].institutions[1].country_code | US |
| authorships[3].institutions[1].display_name | Duke University Hospital |
| authorships[3].author_position | last |
| authorships[3].raw_author_name | Bruce A. Sullenger |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA. |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1097/cp9.0000000000000122 |
| open_access.oa_status | diamond |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Rats subject to extracorporeal membrane oxygenation have improved cardiac function following anticoagulation and reversal with factor IXa aptamer-antidote oligonucleotide pair |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T12352 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9987999796867371 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2746 |
| primary_topic.subfield.display_name | Surgery |
| primary_topic.display_name | Heparin-Induced Thrombocytopenia and Thrombosis |
| related_works | https://openalex.org/W2411561722, https://openalex.org/W4323284267, https://openalex.org/W174166667, https://openalex.org/W2023619243, https://openalex.org/W4386743610, https://openalex.org/W2025062353, https://openalex.org/W1980832026, https://openalex.org/W173534854, https://openalex.org/W2993918291, https://openalex.org/W2111990318 |
| cited_by_count | 1 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 1 |
| locations_count | 3 |
| best_oa_location.id | doi:10.1097/cp9.0000000000000122 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4210203274 |
| best_oa_location.source.issn | 2470-7511, 2470-752X |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2470-7511 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Cardiology Plus |
| best_oa_location.source.host_organization | https://openalex.org/P4310315671 |
| best_oa_location.source.host_organization_name | Lippincott Williams & Wilkins |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310315671 |
| best_oa_location.license | cc-by-nc-nd |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Cardiology Plus |
| best_oa_location.landing_page_url | https://doi.org/10.1097/cp9.0000000000000122 |
| primary_location.id | doi:10.1097/cp9.0000000000000122 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4210203274 |
| primary_location.source.issn | 2470-7511, 2470-752X |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2470-7511 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Cardiology Plus |
| primary_location.source.host_organization | https://openalex.org/P4310315671 |
| primary_location.source.host_organization_name | Lippincott Williams & Wilkins |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310315671 |
| primary_location.license | cc-by-nc-nd |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Cardiology Plus |
| primary_location.landing_page_url | https://doi.org/10.1097/cp9.0000000000000122 |
| publication_date | 2025-04-01 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W2013537866, https://openalex.org/W4306673373, https://openalex.org/W2057382122, https://openalex.org/W4205443023, https://openalex.org/W2138849164, https://openalex.org/W4283366449, https://openalex.org/W2072904489, https://openalex.org/W4288076656, https://openalex.org/W2071283345, https://openalex.org/W4401484377, https://openalex.org/W3024213168, https://openalex.org/W2044389722, https://openalex.org/W4400318347, https://openalex.org/W1981433845, https://openalex.org/W2020115844, https://openalex.org/W1980585134, https://openalex.org/W2126945537, https://openalex.org/W2077040278, https://openalex.org/W2103311193, https://openalex.org/W2029545735, https://openalex.org/W2624114580, https://openalex.org/W2131159842, https://openalex.org/W1981180126, https://openalex.org/W4312212228, https://openalex.org/W1992154972, https://openalex.org/W2117422745, https://openalex.org/W2084652933, https://openalex.org/W10851429, https://openalex.org/W4205940054, https://openalex.org/W2022331928, https://openalex.org/W4405750830, https://openalex.org/W2171713512, https://openalex.org/W4200029428, https://openalex.org/W2080806891, https://openalex.org/W2806708252, https://openalex.org/W1992464047, https://openalex.org/W2075705530, https://openalex.org/W4400488670, https://openalex.org/W1984230417, https://openalex.org/W2034288018, https://openalex.org/W4402551909, https://openalex.org/W3035097134, https://openalex.org/W1991975132, https://openalex.org/W4402740451, https://openalex.org/W2155363644, https://openalex.org/W2194343859, https://openalex.org/W2471550561, https://openalex.org/W2919397938 |
| referenced_works_count | 48 |
| abstract_inverted_index.3 | 187, 202 |
| abstract_inverted_index.5 | 199 |
| abstract_inverted_index.6 | 182 |
| abstract_inverted_index.8 | 194 |
| abstract_inverted_index.= | 218, 239 |
| abstract_inverted_index.P | 217, 238 |
| abstract_inverted_index.a | 60, 67, 79, 110, 249, 287 |
| abstract_inverted_index.(1 | 102 |
| abstract_inverted_index.10 | 254 |
| abstract_inverted_index.30 | 190 |
| abstract_inverted_index.42 | 214 |
| abstract_inverted_index.51 | 197 |
| abstract_inverted_index.54 | 185 |
| abstract_inverted_index.59 | 192 |
| abstract_inverted_index.60 | 136, 210 |
| abstract_inverted_index.IU | 104 |
| abstract_inverted_index.an | 55, 275 |
| abstract_inverted_index.at | 189, 201 |
| abstract_inverted_index.in | 78, 252, 256, 266 |
| abstract_inverted_index.is | 6 |
| abstract_inverted_index.no | 263 |
| abstract_inverted_index.of | 45, 138, 166, 289 |
| abstract_inverted_index.to | 41, 76, 152, 163 |
| abstract_inverted_index.± | 181, 186, 193, 198, 211, 215, 232, 236 |
| abstract_inverted_index.(10 | 114 |
| abstract_inverted_index.(50 | 119 |
| abstract_inverted_index.(58 | 180 |
| abstract_inverted_index.16% | 212 |
| abstract_inverted_index.8%; | 216 |
| abstract_inverted_index.IXa | 62 |
| abstract_inverted_index.The | 141, 154, 270 |
| abstract_inverted_index.UFH | 22 |
| abstract_inverted_index.and | 1, 17, 23, 34, 36, 74, 100, 106, 116, 129, 134, 205, 293 |
| abstract_inverted_index.are | 25 |
| abstract_inverted_index.due | 40 |
| abstract_inverted_index.for | 14, 49, 248, 283 |
| abstract_inverted_index.its | 15, 72, 117 |
| abstract_inverted_index.may | 280 |
| abstract_inverted_index.one | 95 |
| abstract_inverted_index.pig | 47 |
| abstract_inverted_index.rat | 80 |
| abstract_inverted_index.the | 7, 42, 107, 158, 169, 221, 257 |
| abstract_inverted_index.two | 93 |
| abstract_inverted_index.vs. | 184, 196, 213, 234 |
| abstract_inverted_index.(600 | 98 |
| abstract_inverted_index.FIXa | 112, 142 |
| abstract_inverted_index.This | 52 |
| abstract_inverted_index.clot | 149 |
| abstract_inverted_index.into | 92 |
| abstract_inverted_index.mean | 177 |
| abstract_inverted_index.mmHg | 183, 188, 195, 200 |
| abstract_inverted_index.most | 8 |
| abstract_inverted_index.rats | 89 |
| abstract_inverted_index.side | 29 |
| abstract_inverted_index.that | 279 |
| abstract_inverted_index.were | 90, 131, 243 |
| abstract_inverted_index.with | 19, 27, 66, 286, 297 |
| abstract_inverted_index.(HIT) | 292 |
| abstract_inverted_index.(UFH) | 5 |
| abstract_inverted_index.ECMO. | 139 |
| abstract_inverted_index.about | 38 |
| abstract_inverted_index.after | 135 |
| abstract_inverted_index.count | 229 |
| abstract_inverted_index.group | 171, 223 |
| abstract_inverted_index.hours | 203 |
| abstract_inverted_index.other | 108 |
| abstract_inverted_index.prove | 281 |
| abstract_inverted_index.study | 53 |
| abstract_inverted_index.using | 59 |
| abstract_inverted_index.(ECMO) | 84 |
| abstract_inverted_index.(FIXa) | 63 |
| abstract_inverted_index.0.01). | 219 |
| abstract_inverted_index.0.03). | 240 |
| abstract_inverted_index.IU/kg) | 99 |
| abstract_inverted_index.better | 225 |
| abstract_inverted_index.during | 133 |
| abstract_inverted_index.except | 247 |
| abstract_inverted_index.factor | 61 |
| abstract_inverted_index.group. | 259 |
| abstract_inverted_index.impact | 44 |
| abstract_inverted_index.mg/100 | 103 |
| abstract_inverted_index.mg/kg) | 115 |
| abstract_inverted_index.model. | 85 |
| abstract_inverted_index.paired | 65 |
| abstract_inverted_index.safety | 75 |
| abstract_inverted_index.useful | 282 |
| abstract_inverted_index.valued | 13 |
| abstract_inverted_index.(IL-10) | 255 |
| abstract_inverted_index.aptamer | 64, 113, 143, 222, 258, 273 |
| abstract_inverted_index.between | 245 |
| abstract_inverted_index.cardiac | 127, 206 |
| abstract_inverted_index.circuit | 146 |
| abstract_inverted_index.counts, | 124 |
| abstract_inverted_index.farming | 48 |
| abstract_inverted_index.groups, | 246 |
| abstract_inverted_index.groups: | 94 |
| abstract_inverted_index.heparin | 4, 50, 97 |
| abstract_inverted_index.history | 288 |
| abstract_inverted_index.matched | 68 |
| abstract_inverted_index.mg/kg). | 120 |
| abstract_inverted_index.minutes | 137 |
| abstract_inverted_index.patency | 147 |
| abstract_inverted_index.potency | 16 |
| abstract_inverted_index.rapidly | 156 |
| abstract_inverted_index.similar | 162, 244 |
| abstract_inverted_index.without | 148 |
| abstract_inverted_index.However, | 21 |
| abstract_inverted_index.Methods: | 86 |
| abstract_inverted_index.Notably, | 168 |
| abstract_inverted_index.Results: | 140 |
| abstract_inverted_index.analysis | 261 |
| abstract_inverted_index.antidote | 118, 155 |
| abstract_inverted_index.arterial | 178 |
| abstract_inverted_index.assessed | 132 |
| abstract_inverted_index.commonly | 9 |
| abstract_inverted_index.concerns | 37 |
| abstract_inverted_index.effects, | 30 |
| abstract_inverted_index.efficacy | 73 |
| abstract_inverted_index.function | 207 |
| abstract_inverted_index.heparin. | 153, 167 |
| abstract_inverted_index.improved | 176 |
| abstract_inverted_index.increase | 251 |
| abstract_inverted_index.lesions. | 268 |
| abstract_inverted_index.managing | 284 |
| abstract_inverted_index.markers, | 126 |
| abstract_inverted_index.membrane | 82 |
| abstract_inverted_index.minutes; | 191 |
| abstract_inverted_index.patients | 285 |
| abstract_inverted_index.platelet | 123, 226 |
| abstract_inverted_index.pressure | 179 |
| abstract_inverted_index.profiles | 242 |
| abstract_inverted_index.purpose: | 2 |
| abstract_inverted_index.revealed | 262 |
| abstract_inverted_index.reversal | 165 |
| abstract_inverted_index.reversed | 157 |
| abstract_inverted_index.strategy | 58, 278 |
| abstract_inverted_index.superior | 173 |
| abstract_inverted_index.utilized | 10 |
| abstract_inverted_index.(platelet | 228 |
| abstract_inverted_index.activity, | 161 |
| abstract_inverted_index.anti-FIXa | 272 |
| abstract_inverted_index.antidote, | 70 |
| abstract_inverted_index.comparing | 71 |
| abstract_inverted_index.decrease: | 230 |
| abstract_inverted_index.evaluates | 54 |
| abstract_inverted_index.exhibited | 224 |
| abstract_inverted_index.fraction: | 209 |
| abstract_inverted_index.function, | 128 |
| abstract_inverted_index.heparin), | 105 |
| abstract_inverted_index.including | 31, 175 |
| abstract_inverted_index.increased | 32 |
| abstract_inverted_index.morbidity | 33 |
| abstract_inverted_index.outcomes, | 174 |
| abstract_inverted_index.protamine | 24, 101, 298 |
| abstract_inverted_index.receiving | 96, 109 |
| abstract_inverted_index.transient | 250 |
| abstract_inverted_index.Background | 0 |
| abstract_inverted_index.associated | 26, 296 |
| abstract_inverted_index.comparable | 151 |
| abstract_inverted_index.formation, | 150 |
| abstract_inverted_index.maintained | 145 |
| abstract_inverted_index.mortality, | 35 |
| abstract_inverted_index.myocardial | 267, 294 |
| abstract_inverted_index.post-ECMO) | 204 |
| abstract_inverted_index.protamine. | 20 |
| abstract_inverted_index.randomized | 91 |
| abstract_inverted_index.represents | 274 |
| abstract_inverted_index.−288,000 | 231 |
| abstract_inverted_index.−404,000 | 235 |
| abstract_inverted_index.(shortening | 208 |
| abstract_inverted_index.121,000/μL | 233 |
| abstract_inverted_index.89,000/μL; | 237 |
| abstract_inverted_index.Coagulation | 121 |
| abstract_inverted_index.Twenty-four | 87 |
| abstract_inverted_index.alternative | 56, 276 |
| abstract_inverted_index.aptamer’s | 159 |
| abstract_inverted_index.differences | 265 |
| abstract_inverted_index.dysfunction | 295 |
| abstract_inverted_index.effectively | 144 |
| abstract_inverted_index.large-scale | 46 |
| abstract_inverted_index.oxygenation | 83 |
| abstract_inverted_index.parameters, | 122 |
| abstract_inverted_index.production. | 51 |
| abstract_inverted_index.rapid-onset | 11 |
| abstract_inverted_index.significant | 28, 264 |
| abstract_inverted_index.Conclusions: | 269 |
| abstract_inverted_index.Inflammatory | 241 |
| abstract_inverted_index.demonstrated | 172 |
| abstract_inverted_index.inflammatory | 125 |
| abstract_inverted_index.interleukins | 253 |
| abstract_inverted_index.preservation | 227 |
| abstract_inverted_index.Additionally, | 220 |
| abstract_inverted_index.anticoagulant | 57, 160, 277 |
| abstract_inverted_index.environmental | 43 |
| abstract_inverted_index.protamine’s | 164 |
| abstract_inverted_index.reversibility | 18 |
| abstract_inverted_index.Sprague-Dawley | 88 |
| abstract_inverted_index.Unfractionated | 3 |
| abstract_inverted_index.anticoagulant, | 12 |
| abstract_inverted_index.extracorporeal | 81 |
| abstract_inverted_index.histopathology | 130 |
| abstract_inverted_index.sustainability | 39 |
| abstract_inverted_index.administration. | 299 |
| abstract_inverted_index.heparin-induced | 290 |
| abstract_inverted_index.oligonucleotide | 69 |
| abstract_inverted_index.aptamer-antidote | 170 |
| abstract_inverted_index.thrombocytopenia | 291 |
| abstract_inverted_index.Histopathological | 260 |
| abstract_inverted_index.heparin-protamine | 77 |
| abstract_inverted_index.antidote-controlled | 271 |
| abstract_inverted_index.cholesterol-modified | 111 |
| cited_by_percentile_year.max | 95 |
| cited_by_percentile_year.min | 91 |
| countries_distinct_count | 2 |
| institutions_distinct_count | 4 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/12 |
| sustainable_development_goals[0].score | 0.46000000834465027 |
| sustainable_development_goals[0].display_name | Responsible consumption and production |
| sustainable_development_goals[1].id | https://metadata.un.org/sdg/15 |
| sustainable_development_goals[1].score | 0.44999998807907104 |
| sustainable_development_goals[1].display_name | Life in Land |
| citation_normalized_percentile.value | 0.92559584 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |